A Comprehensive Monograph on Omega-3-Acid Ethyl Esters: Pharmacology, Clinical Evidence, and Evolving Regulatory Landscape

Executive Summary

Omega-3-acid ethyl esters represent a specific, prescription-grade pharmaceutical formulation composed of a purified mixture of ethyl esters of omega-3 polyunsaturated fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), derived from fish oil. This agent holds a single, undisputed indication in the United States and Europe: as an adjunct to diet for the reduction of triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (sHTG), defined as TG levels of 500 mg/dL or greater. Its mechanism of action is multifactorial but centered on the liver, where it reduces triglyceride synthesis and VLDL particle production while enhancing fatty acid oxidation.

The clinical profile of omega-3-acid ethyl esters is characterized by a fundamental dichotomy. On one hand, its efficacy in lowering markedly elevated triglycerides is well-established through numerous clinical trials, demonstrating TG reductions of 20% to 45%. On the other hand, its role in reducing the risk of major cardiovascular events is highly controversial and largely unsupported by the weight of modern, high-quality clinical evidence. The initial promise suggested by early studies has not been consistently replicated in subsequent, more rigorous cardiovascular outcome trials (CVOTs). This has led to a significant divergence in its regulatory status, with European authorities withdrawing the post-myocardial infarction secondary prevention indication, a status it never formally held in the U.S.

A critical aspect of this drug's profile is its distinction from the EPA-only formulation, icosapent ethyl. The combination of EPA and DHA in omega-3-acid ethyl esters is associated with a potential increase in low-density lipoprotein cholesterol (LDL-C), an effect attributed to the DHA component that is not observed with EPA-only therapy. This difference is considered a key factor in the divergent outcomes of their respective landmark CVOTs.

Furthermore, the risk-benefit assessment of omega-3-acid ethyl esters has been fundamentally altered by recent, compelling evidence. Systematic reviews and meta-analyses of large clinical trials have revealed a clear, dose-dependent increased risk of developing atrial fibrillation (AF) in patients with or at risk for cardiovascular disease. This finding has prompted major regulatory action in Europe, where AF is now listed as a common side effect, and has led to the clinical mandate that the drug be permanently discontinued if AF develops. Consequently, the therapeutic position of omega-3-acid ethyl esters is now more narrowly defined as a targeted therapy for sHTG, where the benefits of triglyceride reduction must be carefully weighed against the risks of potential LDL-C elevation and the development of atrial fibrillation.

Drug Identification and Physicochemical Properties

Nomenclature and Identification

Establishing a precise identity for this pharmaceutical agent is crucial, as it distinguishes it from non-prescription dietary supplements. The standardized nomenclature and identifiers are as follows:

• Generic Name: Omega-3-acid ethyl esters [1]
• DrugBank ID: DB09539 [1]
• Type: Small Molecule [4]
• CAS Number: 308081-97-2 [5]
• Synonyms: A variety of synonyms are used in chemical and commercial contexts, including Omega-3-Acid, Ethyl Esters; Omega 3 Fatty Acid; Polyunsaturated ω-3 fatty acids, Et esters; and Fatty acids, polyunsatd., omega-3, Et esters.[7]
• Common Brand Names: The most widely recognized brand name is Lovaza. Other brand names include Omacor (an earlier name for Lovaza and still used in some regions), Omtryg, Vascazen, Triklo, and Teromeg.[5]
• Therapeutic Classification: The agent is classified as an Antilipemic or Lipid-Lowering Agent.[5]

Chemical Composition and Structure

Omega-3-acid ethyl esters are not a single chemical entity but a complex, purified, and standardized mixture derived from natural sources.

• Source and General Description: The active substance is a mixture of ethyl esters of long-chain omega-3 polyunsaturated fatty acids (PUFAs), which are extracted and purified from the body oils of various fish species.[3] It presents as a light-yellow liquid that possesses a slight, characteristic fish-like odor. In terms of solubility, it is practically insoluble in water but demonstrates high solubility in organic solvents such as acetone, dehydrated alcohol, heptane, and methanol.[5]
• Principal Active Components: The therapeutic activity is primarily attributed to a combination of two principal omega-3 fatty acid ethyl esters:
• Eicosapentaenoic Acid (EPA) ethyl ester
• Docosahexaenoic Acid (DHA) ethyl ester [3]
• Quantitative Composition: The pharmaceutical-grade product is highly concentrated and standardized. For the Lovaza and Omacor formulations, each 1-gram transparent, soft-gelatin capsule contains at least 900 mg of total omega-3-acid ethyl esters. This total amount is specifically composed of:
• Approximately 465 mg of EPA ethyl ester
• Approximately 375 mg of DHA ethyl ester [11]

The sum of these two principal components is specified by the United States Pharmacopeia (USP) to be within the range of 800-880 mg per gram of encapsulated oil.18

• Other Omega-3 Components: The rigor of its pharmaceutical standardization is further underscored by the USP monograph, which defines the Active Pharmaceutical Ingredient (API) as a composite of at least seven distinct omega-3-acid ethyl ester components. Beyond the primary EPA and DHA esters, the monograph specifies quantitative ranges for three other components present at lower concentrations: moroctic acid ethyl ester (SDAee), heneicosapentaenoic acid ethyl ester (HPAee), and docosapentaenoic acid ethyl ester (DPAee). It also mandates the presence of eicosatetraenoic acid ethyl ester (ETAee).[18] This precise, multi-component specification is a fundamental differentiator between the regulated drug product and the highly variable, often unverified compositions of over-the-counter (OTC) fish oil supplements. The clinical trial results, safety warnings, and regulatory actions detailed in this report apply exclusively to this well-defined pharmaceutical mixture and cannot be reliably extrapolated to the consumer-grade supplement market.
• Inactive Ingredients: The formulation includes non-active components essential for stability and delivery. These include approximately 4 mg of α-tocopherol (an antioxidant, typically in a soybean oil carrier) to prevent lipid peroxidation, and gelatin, glycerol, and purified water, which constitute the capsule shell.[12]

The distinct chemical properties of the two principal components and the overall mixture are summarized in Table II.1.

Table II.1: Physicochemical Properties of Omega-3-Acid Ethyl Esters and Principal Components

Property	EPA Ethyl Ester (Icosapent Ethyl)	DHA Ethyl Ester (Ethyl Docosahexaenoate)	Combined Product (Lovaza Mixture Representation)
IUPAC Name	ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate 19	ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate 19	ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate 19
Molecular Formula	C22​H34​O2​ 17	C24​H36​O2​ 17	C46​H70​O4​ 19
Molecular Weight (g/mol)	330.51 17	356.55 17	687.0 19
CAS Number	86227-47-6 20	81926-94-5 23	861006-80-6 19
Appearance	-	-	Light yellow liquid, slight fish-like odor 5
Solubility	-	-	Practically insoluble in water; very soluble in acetone, ethanol, heptane 5

The data in this table visually reinforces the fundamental concept that Omega-3-acid ethyl esters function as a combination therapy delivered within a single capsule. This composition is central to understanding the subsequent discussions on its integrated pharmacology and clinical effects, where the actions of EPA and DHA may differ or, in some cases, such as their effect on LDL-cholesterol, produce distinct and clinically relevant outcomes.

Comprehensive Pharmacological Profile

The therapeutic effects of omega-3-acid ethyl esters are derived from a complex interplay of mechanisms primarily affecting hepatic lipid metabolism, as well as broader pharmacodynamic effects on hemostasis and inflammation.

Mechanism of Action

While the complete mechanism of action is not fully elucidated, the primary locus of activity is the liver, where the drug modulates the synthesis and catabolism of fatty acids.[14] The principal mechanisms include:

• Inhibition of Triglyceride Synthesis: The core therapeutic action is a reduction in the hepatic synthesis of triglycerides.[4] This is achieved through at least two pathways. First, EPA and DHA are poor substrates for the enzymes responsible for triglyceride synthesis, namely acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT).[4] By inhibiting DGAT, they reduce the final step in triglyceride assembly. Second, they competitively inhibit the esterification of other fatty acids, further limiting the building blocks available for triglyceride production.[29]
• Enhanced Fatty Acid Catabolism: The drug promotes an increase in the β-oxidation of fatty acids within hepatic peroxisomes.[4] This metabolic shift enhances the breakdown of fatty acids for energy, thereby reducing the intracellular pool of free fatty acids that would otherwise be available for triglyceride synthesis.[16]
• Reduced VLDL Production and Secretion: Triglycerides are exported from the liver packaged within Very Low-Density Lipoprotein (VLDL) particles. By directly inhibiting triglyceride synthesis, omega-3-acid ethyl esters consequently reduce the assembly and secretion of VLDL from the liver.[28] This leads to lower levels of circulating VLDL, the main carrier of triglycerides in the blood.

Pharmacodynamics

The mechanisms of action translate into a distinct profile of observable physiological and biochemical effects.

• Effects on Lipid Profile:
• Triglycerides (TG): The primary and most consistent pharmacodynamic effect is a significant, dose-dependent reduction in fasting plasma triglyceride concentrations.[10]
• VLDL-Cholesterol (VLDL-C): Concurrent with the fall in triglycerides, a reduction in VLDL-C is observed, reflecting the decreased number of circulating VLDL particles.[29]
• Low-Density Lipoprotein Cholesterol (LDL-C): A critical and clinically significant pharmacodynamic effect is the potential for omega-3-acid ethyl esters to increase LDL-C levels in some patients, particularly those with baseline severe hypertriglyceridemia.[11] This effect necessitates regular monitoring of the lipid panel. The dual composition of the drug is at the root of this complex profile. The DHA component is believed to be primarily responsible for the increase in LDL-C, an effect not shared to the same extent by EPA. This mechanistic distinction is a key differentiator from EPA-only therapies and likely contributed to the divergent clinical outcomes observed in cardiovascular trials of EPA/DHA combination products versus EPA-only products.
• High-Density Lipoprotein Cholesterol (HDL-C): While DHA may contribute to a rise in HDL-C ("good cholesterol"), the overall effect of the combined product on HDL-C is generally small, inconsistent, and significantly less pronounced than the HDL-C elevation seen with fibrate therapy.[29]
• Effects on Hemostasis and Inflammation:
• Hemostasis: Treatment with omega-3-acid ethyl esters leads to a decrease in the production of thromboxane A2, a potent platelet aggregator and vasoconstrictor. This results in a slight prolongation of bleeding time.[29] While this effect on its own does not typically exceed normal physiological limits or cause clinically significant bleeding episodes, it forms the basis for the cautionary warnings regarding concomitant use with anticoagulant or antiplatelet medications.[11]
• Inflammation: Beyond lipid modulation, omega-3 fatty acids possess broader biological activities. They can be incorporated into cell membranes and, upon release, serve as precursors for the synthesis of specialized pro-resolving lipid mediators (SPMs), such as resolvins and protectins. These molecules actively promote the resolution of inflammation and tissue injury, suggesting potential atheroprotective properties that are independent of triglyceride lowering.[37]

Pharmacokinetics

The absorption, distribution, metabolism, and elimination (ADME) profile of omega-3-acid ethyl esters is analogous to that of other dietary lipids.

• Absorption: Following oral administration, the ethyl ester prodrugs are not absorbed intact. They first undergo hydrolysis in the intestinal lumen, a reaction catalyzed by pancreatic lipase, which cleaves the ester bond to release free fatty acids (EPA and DHA) and ethanol.[4] These free fatty acids are then absorbed by the enterocytes. The ethyl ester formulation is known to have lower bioavailability compared to triglyceride or free fatty acid forms of omega-3s, precisely because it is dependent on this enzymatic digestion step.[38] This pharmacokinetic property provides the rationale for the clinical recommendation to administer the drug with meals, as food intake stimulates the secretion of pancreatic lipase, thereby enhancing the hydrolysis and subsequent absorption of the active fatty acids.[15]
• Distribution: After absorption into the enterocytes, the free fatty acids are re-esterified and packaged into chylomicrons, which enter the systemic circulation via the lymphatic system.[4] From the circulation, EPA and DHA are widely distributed throughout the body and incorporated into the phospholipid membranes of cells in various tissues, as well as into plasma lipid pools like triglycerides and cholesterol esters.[4] This extensive and rapid incorporation into endogenous lipid structures makes traditional pharmacokinetic assessments of bioavailability and protein binding challenging.[4] However, it is known that the majority of the EPA component is bound to plasma proteins, primarily albumin.[4] The apparent volume of distribution for EPA has been reported as 82 ± 56 L.[4]
• Metabolism: The liver is the central organ for the metabolism of circulating EPA and DHA.[4] In the liver, these fatty acids can follow several metabolic pathways: they can be stored in hepatic lipid pools, incorporated into lipoproteins (primarily VLDL) for transport to peripheral tissues, or, most significantly, undergo β-oxidation to produce acetyl-CoA, which enters the citric acid cycle to generate energy.[4]
• Elimination: The primary route of elimination for omega-3 fatty acids is through oxidative catabolism, where they are utilized as an energy source by most tissues in the body. The ultimate end products of this process are carbon dioxide and water.[4] The elimination half-life is long, reported to be approximately 79 ± 47 hours.[4]

Clinical Efficacy and Investigational Use

The clinical utility of omega-3-acid ethyl esters is well-defined for its primary indication but becomes considerably more complex and controversial when considering its effects on cardiovascular outcomes and other investigational areas.

Approved Indication: Severe Hypertriglyceridemia (sHTG)

The core, evidence-backed role for omega-3-acid ethyl esters is in the management of severely elevated triglycerides.

• Indication Statement: The drug is approved by the U.S. Food and Drug Administration (FDA) and other regulatory bodies as an adjunct to diet for the purpose of reducing triglyceride (TG) levels in adult patients with severe hypertriglyceridemia, which is defined as a fasting TG level of 500 mg/dL or greater.[3]
• Limitations of Use: The official prescribing information carries important limitations. It explicitly states that the effect of the drug on reducing the risk of pancreatitis in patients with sHTG has not been determined. Furthermore, the effect on cardiovascular mortality and morbidity in this specific high-triglyceride population has not been established.[34]
• Pivotal Trial Evidence: The approval for this indication is supported by a consistent body of evidence from randomized, placebo-controlled trials:
• Multiple studies have demonstrated that a dose of 4 g/day effectively lowers triglyceride levels by a range of 20% to 45%. The magnitude of this reduction is generally proportional to the baseline triglyceride level, with greater reductions seen in patients with higher starting values.[31]
• A multicenter, randomized, double-blind, placebo-controlled trial conducted in a Taiwanese population with triglyceride levels ranging from 200–1000 mg/dL found that 4 g/day of omega-3-acid ethyl esters reduced triglycerides by a median of -32.1% over eight weeks, compared to a -5.4% reduction in the placebo group (p<0.001).[31]
• A more recent multicenter, randomized, double-blind, placebo-controlled study involving 239 patients with severe HTG confirmed these findings. After 12 weeks of treatment, the omega-3 group showed statistically significant decreases in triglycerides (TAG), total cholesterol (TC), non-HDL-C, and VLDL-C compared to the placebo group, all while maintaining a tolerable safety profile.[42]
• The design of a key Phase 3 trial (NCT02625870) further illustrates the standard for evidence in this area, comparing 4 g/day of the drug against a corn oil placebo over 12 weeks in subjects with baseline TGs ≥500 mg/dL but <2000 mg/dL.[43]
• Use with Statins: Omega-3-acid ethyl esters can be used effectively in combination with HMG-CoA reductase inhibitors (statins). Clinical studies have shown that when added to statin therapy, the drug provides an additive effect, further reducing triglyceride and VLDL-cholesterol concentrations beyond what is achieved with the statin alone.[5]

Cardiovascular Outcomes: A Complex and Evolving Picture

In stark contrast to its clear efficacy in lipid modification, the role of omega-3-acid ethyl esters in reducing the risk of cardiovascular events is fraught with inconsistency and controversy. The body of evidence has evolved significantly over time, leading to a re-evaluation of its place in cardiovascular protection.

• Post-Myocardial Infarction (Post-MI):
• GISSI-Prevenzione Study (1999): This large, open-label Italian study was foundational to the drug's initial use in cardiology. In over 11,000 patients with a recent myocardial infarction, treatment with a low dose (1 g/day) of omega-3-acid ethyl esters was associated with a statistically significant reduction in the primary composite endpoint of all-cause death, non-fatal MI, and non-fatal stroke.[29] These results formed the basis for the drug's approval for post-MI secondary prevention in Europe.[30]
• OMEGA-REMODEL Trial: This more recent and rigorous, albeit smaller, double-blind, randomized controlled trial painted a different picture. It randomized 358 patients with acute MI to a high dose (4 g/day) or placebo for six months. In the long-term follow-up, which extended for a median of 6.6 years, the intention-to-treat analysis found no significant reduction in the primary MACE endpoint or any of its individual components.[45] This failure to replicate the benefit of the earlier GISSI-P trial, even with a higher dose, contributed to the growing skepticism about the drug's role in this setting.
• Primary and Secondary Prevention in Broader Populations:
• VITAL and ASCEND Trials: These two large-scale primary prevention trials tested a low dose (840 mg/day) of omega-3-acid ethyl esters. In the VITAL trial, conducted in over 25,000 individuals, the drug did not significantly reduce the primary composite endpoint of major cardiovascular events.[46] Similarly, in the ASCEND trial of over 15,000 patients with diabetes, the primary endpoint was not met.[46] However, both trials did show signals of potential benefit in pre-specified secondary analyses. VITAL reported a significant 28% reduction in the risk of heart attacks and a 50% reduction in fatal heart attacks, while ASCEND reported a significant 19% reduction in cardiovascular death.[46] These positive secondary findings, while hypothesis-generating, were overshadowed by the failure to meet the primary goals.
• The Icosapent Ethyl (Vascepa) Comparator: The narrative of omega-3 fatty acids in cardiovascular prevention was dramatically altered by the REDUCE-IT trial. This study used a high dose (4 g/day) of icosapent ethyl, a prescription product containing only the EPA ethyl ester. In high-risk patients already on statin therapy, icosapent ethyl demonstrated a robust and statistically significant 25% relative risk reduction in the primary composite endpoint of major adverse cardiovascular events.[33] The starkly positive result of REDUCE-IT, compared to the largely null or inconsistent results for the EPA/DHA combination product, has become a central point of debate, suggesting that the presence of DHA may either fail to provide benefit or potentially attenuate the benefits of EPA in the context of cardiovascular event reduction.

Investigational and Other Clinical Uses

Beyond its primary indication, omega-3-acid ethyl esters have been investigated for a range of other conditions, reflecting the broad biological activities of its components.

• Nonalcoholic Fatty Liver Disease (NAFLD/NASH): A completed Phase 4 clinical trial (NCT00760513) was conducted to evaluate the use of n-3 fatty acids for the treatment of NAFLD, a condition often associated with hypertriglyceridemia.[1]
• Cardiovascular Disease (Basic Science): The drug was studied in combination with fenofibrate in a completed basic science trial (NCT01048502) to investigate its potential to modulate endotoxemia, a factor implicated in systemic inflammation and cardiovascular risk.[47]
• Oncology: The agent is being explored in supportive care settings. It is a component of a multi-modal intervention being tested in a Phase 2 trial (NCT04907864) aimed at managing cachexia (severe wasting) in patients with advanced biliary cancers.[48] Additionally, an active clinical trial is evaluating its use in combination with low-dose tamoxifen for the potential reduction of breast cancer risk.[49]
• Atrial Fibrillation (AF): In a notable example of evolving scientific understanding, a large, randomized, placebo-controlled trial (NCT00402363) was sponsored by GlaxoSmithKline to specifically evaluate if Lovaza could prevent recurrent, symptomatic atrial fibrillation.[50] This initial hypothesis, likely based on preclinical data suggesting anti-arrhythmic properties, stands in direct contrast to the later clinical trial evidence and regulatory warnings that have now firmly established that the drug can, in fact, cause atrial fibrillation. This reversal highlights the critical importance of large-scale, long-term safety data in defining a drug's true clinical profile, which can sometimes overturn prevailing hypotheses.

The complexity and often conflicting results from major clinical trials are summarized in Table IV.1. This side-by-side comparison starkly illustrates the narrative of consistent efficacy in lipid-lowering versus inconsistent and largely null results in cardiovascular outcome trials. It also highlights the critical impact of variables such as dose, patient population, and specific formulation (EPA/DHA vs. EPA-only) in determining clinical outcomes.

Table IV.1: Summary of Major Clinical Trials for Omega-3-Acid Ethyl Esters and Comparators

Trial Name	Indication / Population	N	Drug & Dose	Comparator	Primary Endpoint Result	Key Secondary/Subgroup Findings & Notes	Source(s)
GISSI-Prevenzione	Post-Myocardial Infarction	11,324	Omega-3-acid ethyl esters 1 g/day	No treatment (open-label)	Positive: Significant reduction in combined endpoint (all-cause death, non-fatal MI, non-fatal stroke).	Basis for original European post-MI indication. Effect not confirmed in later, more rigorous trials.	29
OMEGA-REMODEL	Acute Myocardial Infarction	358	Omega-3-acid ethyl esters 4 g/day	Placebo	Negative: No significant reduction in MACE at long-term follow-up.	Responder Analysis: Patients who achieved a ≥5% increase in omega-3 index had significantly lower MACE rates.	45
VITAL	Primary CV Prevention	25,871	Omega-3-acid ethyl esters 840 mg/day	Placebo	Negative: No significant reduction in the composite of major CV events or cancer.	Positive Secondary Endpoints: 28% reduction in MI, 50% reduction in fatal MI. Benefit greater in those with low fish intake and in African Americans.	46
ASCEND	Primary CV Prevention (Diabetes)	15,480	Omega-3-acid ethyl esters 840 mg/day	Olive Oil Placebo	Negative: No significant reduction in the composite of serious vascular events.	Positive Secondary Endpoint: 19% reduction in cardiovascular death.	46
REDUCE-IT	High CV Risk + Hypertriglyceridemia (on statin)	8,179	Icosapent Ethyl (EPA-only) 4 g/day	Mineral Oil Placebo	Strongly Positive: 25% relative risk reduction in major adverse cardiovascular events.	Key comparator trial highlighting the success of high-dose, EPA-only therapy.	33
Taiwanese HTG Trial	Hypertriglyceridemia (TG 200-1000 mg/dL)	253	Omega-3-acid ethyl esters 4 g/day or 2 g/day	Placebo	Positive: Significant TG reduction of -32.1% (4g) and -29.7% (2g) vs. -5.4% for placebo.	Confirms robust TG-lowering efficacy.	31

A particularly insightful finding emerges from the OMEGA-REMODEL trial, which suggests a potential shift away from a "one-size-fits-all" approach. The observation that clinical benefit was confined to patients who achieved a measurable biological response (a ≥5% increase in the red blood cell omega-3 index) introduces a "responder versus non-responder" paradigm.[45] This implies that the therapeutic efficacy of the drug may not be guaranteed by prescription alone but might depend on achieving a specific biomarker target. This points toward a potential future where clinical practice could incorporate the monitoring of the omega-3 index to guide therapy, titrate dosage, and identify patients who are most likely to benefit, moving the use of this agent closer to a personalized medicine strategy.

Safety, Tolerability, and Risk Management

The safety profile of omega-3-acid ethyl esters has evolved significantly, with recent data fundamentally altering the risk-benefit calculation. While generally associated with minor gastrointestinal side effects, the emergence of a clear, dose-dependent risk for atrial fibrillation has become a primary safety concern.

Adverse Reactions

Data from clinical trials and postmarketing surveillance have identified a consistent pattern of adverse reactions.

• Most Common Adverse Reactions: In pooled analyses of clinical trials, the most frequently reported adverse reactions, occurring at a higher rate than placebo, are primarily gastrointestinal in nature. These include:
• Eructation (burping)
• Dyspepsia (indigestion or upset stomach)
• Taste perversion (bad, unusual, or unpleasant aftertaste) [10]
• Other Reported Side Effects: Other less common side effects reported in clinical trials include back pain, flu-like syndrome, and various infections.[11] Additional gastrointestinal complaints such as diarrhea, constipation, excess gas, and nausea or vomiting have also been noted.[51]
• Postmarketing Experience: Spontaneous reports from post-approval use have identified rare but serious events, including anaphylactic reactions, hemorrhagic diathesis (a tendency to bleed or bruise easily), and urticaria (hives).[11]

Serious Adverse Events and Risks of Clinical Concern

Beyond common side effects, several serious risks require active clinical monitoring and management.

• Atrial Fibrillation and Flutter (AF): This represents the most significant safety risk to have emerged in recent years.
• The Risk: A comprehensive review of systematic overviews and meta-analyses of large, randomized, controlled clinical studies has established a dose-dependent increased risk of developing new-onset atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors who are treated with omega-3-acid ethyl esters, compared to placebo.[13] The observed risk is highest at the therapeutic dose of 4 g/day.[53]
• Regulatory Response and Incidence: This evidence prompted major regulatory action. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have mandated updates to the product information, classifying atrial fibrillation as a "common" side effect, which may affect up to 1 in 10 people.[13] The calculated incidence from the reviewed data is approximately 3.9% in at-risk populations.[13]
• Clinical Mandate: The clinical recommendation is unequivocal. If a patient develops atrial fibrillation while on therapy, treatment with omega-3-acid ethyl esters should be permanently discontinued.[13]
• Lipoprotein Profile Changes:
• LDL-C Increase: As noted in its pharmacodynamic profile, the drug may cause a clinically significant increase in low-density lipoprotein cholesterol (LDL-C) levels. This effect is particularly pronounced in patients with severe hypertriglyceridemia. Therefore, periodic monitoring of the full lipoprotein profile, including LDL-C, is a required part of therapy management.[11]
• Bleeding Risk:
• Mechanism: The drug's inhibition of thromboxane A2 production can impair platelet aggregation, leading to a prolongation of bleeding time.[29]
• Clinical Management: While this effect is not typically associated with clinically significant bleeding episodes when the drug is used as monotherapy, it creates a potential for increased risk when combined with other medications that affect coagulation. Patients receiving concomitant therapy with anticoagulants (e.g., warfarin, dabigatran, apixaban) or antiplatelet agents (e.g., clopidogrel, aspirin) must be monitored periodically for signs of increased bleeding.[4]
• Hypersensitivity:
• Risk: As the active ingredients are derived from fish oils, there is a potential for allergic reactions in susceptible individuals. The drug should be used with caution in patients with a known allergy or hypersensitivity to fish and/or shellfish.[12]
• Serious Reactions: Anaphylactic reactions, though rare, have been reported in postmarketing experience and represent a contraindication to the drug's use.[12]
• Hepatic Effects:
• Monitoring: In patients with pre-existing hepatic impairment, liver function should be monitored, as elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels can occur. Periodic monitoring of ALT and AST concentrations is recommended during therapy for these patients.[12]

Drug-Drug Interactions

The primary clinically relevant drug interactions for omega-3-acid ethyl esters relate to their effect on hemostasis.

• Anticoagulants and Antiplatelet Agents: This is the most significant class of interactions. Due to the potential for prolonged bleeding time, co-administration with any drug that affects coagulation requires caution and enhanced monitoring. This includes oral anticoagulants (e.g., warfarin, dabigatran, apixaban, rivaroxaban), antiplatelet drugs (e.g., clopidogrel, aspirin, ticlopidine), and parenteral anticoagulants (e.g., heparin).[4]
• Statins: No clinically significant pharmacokinetic interactions have been observed. Co-administration with simvastatin and other statins does not meaningfully alter the exposure to either the statin or its active metabolites.[12]
• Drugs that Exacerbate Hypertriglyceridemia: The efficacy of omega-3-acid ethyl esters can be undermined by concomitant medications that raise triglyceride levels. Before initiating therapy, consideration should be given to discontinuing or changing drugs known to exacerbate hypertriglyceridemia, such as certain beta-blockers, thiazide diuretics, and estrogens.[34]

Contraindications and Precautions

• Contraindications: The sole absolute contraindication is a known hypersensitivity (e.g., an anaphylactic reaction) to omega-3-acid ethyl esters or any of the components in the formulation.[12]
• Precautions and Warnings:
• Fish/Shellfish Allergy: Use with caution in patients with a history of allergy to fish or shellfish.[12]
• History of Atrial Fibrillation: Use with caution in patients with a history of paroxysmal or persistent atrial fibrillation or flutter, as the drug may be associated with more frequent recurrences, especially in the first few months of therapy.[15]
• Comorbid Conditions: Use with caution in patients with diabetes, hypothyroidism, or pancreas problems, as these conditions can affect or be affected by lipid metabolism.[51]
• Laboratory Monitoring: Regular monitoring of the lipid profile (TG and LDL-C) is essential for all patients. Monitoring of liver enzymes (ALT, AST) is required for patients with hepatic impairment.[15]

A structured approach to risk management is essential for the safe use of this medication. Table V.1 provides a practical, actionable framework for clinicians, linking each major clinical risk to its rationale, required monitoring, and specific management strategy.

Table V.1: Risk Management and Monitoring for Omega-3-Acid Ethyl Esters

Clinical Risk	Mechanism / Rationale	Required Monitoring	Management / Action	Source(s)
Atrial Fibrillation	Dose-dependent pro-arrhythmic effect identified in large RCTs. Risk is highest at 4 g/day in patients with or at risk for CVD.	Clinical monitoring for symptoms (palpitations, dizziness, shortness of breath, fatigue).	Advise patient to seek immediate medical attention if symptoms occur. If AF is diagnosed, permanently discontinue treatment.	13
Increased LDL-C	Pharmacodynamic effect of the drug, primarily attributed to the DHA component.	Periodic monitoring of the full lipid profile, including LDL-C, before and during therapy.	Assess overall cardiovascular risk profile. Consider if the benefit of TG lowering outweighs the risk of LDL-C elevation. May require adjustment of other lipid-lowering therapies (e.g., statin).	15
Bleeding Risk	Inhibition of thromboxane A2 production leading to prolonged bleeding time and impaired platelet aggregation.	Periodic monitoring for signs of increased bleeding (e.g., easy bruising, prolonged bleeding from cuts, black stools) especially in patients on concomitant therapy.	Use with caution with anticoagulants or antiplatelet agents. No routine lab monitoring is specified, but clinical vigilance is required.	4
Hypersensitivity	Drug is derived from fish sources. Potential for allergic reaction in sensitized individuals.	Obtain patient history regarding allergies to fish and/or shellfish before initiating therapy.	Use with caution in patients with known fish/shellfish allergy. Discontinue immediately if signs of an allergic reaction (e.g., hives, anaphylaxis) occur. Contraindicated in patients with known hypersensitivity.	12
Hepatic Impairment	Potential for elevation of liver transaminases (ALT, AST).	In patients with known hepatic impairment, obtain baseline liver function tests and monitor ALT and AST levels periodically during therapy.	If transaminase levels rise significantly, assess risk vs. benefit of continued therapy.	12

Regulatory and Prescribing Information

The regulatory history and current prescribing guidelines for omega-3-acid ethyl esters reveal a significant divergence between major global markets, primarily the United States and Europe. This divergence is a direct reflection of the evolving standards of evidence for cardiovascular therapies over the past two decades.

Global Regulatory Status

• U.S. Food and Drug Administration (FDA):
• Initial Approval and Branding: The product was first approved by the FDA on November 10, 2004, under the brand name Omacor, developed by Reliant Pharmaceuticals. The approved indication was for the treatment of severe hypertriglyceridemia.[60] The brand name was subsequently changed to Lovaza, which became the more widely recognized name in the U.S..[10]
• Generic Availability: The patent exclusivity period for Lovaza ended, leading to the approval of the first generic version, from Teva Pharmaceuticals, on April 7, 2014.[40] Since then, numerous other manufacturers have received approval for generic omega-3-acid ethyl esters capsules, making the treatment more widely accessible.[63]
• Current Indication: The FDA-approved indication has remained consistent since its initial approval. It is authorized as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.[3] It does not hold an indication for cardiovascular risk reduction in the U.S.
• European Medicines Agency (EMA) & UK MHRA:
• Initial Dual Indication: In contrast to the U.S., the drug was originally approved in Europe for two indications: the treatment of hypertriglyceridemia and, notably, for secondary prevention after myocardial infarction. The post-MI indication was granted at a dose of 1 g/day and was based on the results of the GISSI-Prevenzione study.[29]
• Withdrawal of Post-MI Indication (2018): This represents a major regulatory divergence from the U.S. In 2018, the EMA's Committee for Medicinal Products for Human Use (CHMP) conducted a formal re-evaluation of the drug's efficacy. After reviewing the cumulative evidence from newer, more rigorous randomized controlled trials and meta-analyses that failed to confirm the cardiovascular benefit seen in the original open-label GISSI-P study, the CHMP concluded that the drug was no longer effective for this purpose. The risk-benefit balance for the post-MI indication was deemed negative, and this indication was formally withdrawn across the European Union.[30]
• Atrial Fibrillation Warning (2023-2024): A second major regulatory action occurred more recently. Following a comprehensive safety review of pooled trial data, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) and the UK's MHRA identified a dose-dependent increased risk of atrial fibrillation. This led to a mandate to update the Summary of Product Characteristics to list atrial fibrillation as a "common" adverse reaction and to recommend the permanent discontinuation of the drug if AF develops.[13]

The differing regulatory histories serve as a compelling case study in how the interpretation of a drug's value can change over time. Both the FDA and EMA initially evaluated the same foundational data. However, as new evidence accumulated that challenged the original findings, the EMA conducted a proactive, formal review that led to a change in the approved indications. This highlights that a drug's regulatory status is not static but is a dynamic assessment that must adapt as the totality of scientific evidence evolves.

Dosage and Administration

The prescribing information for the approved indication of severe hypertriglyceridemia is consistent across regions.

• Recommended Dosing: The standard therapeutic dose is 4 grams per day.[11]
• Administration: This daily dose can be administered in one of two ways for patient convenience:
• As a single 4-gram dose (four 1-gram capsules taken once daily).
• As two 2-gram doses (two 1-gram capsules taken twice daily). [11]
• Instructions for Use: Patients should be advised to swallow the capsules whole. The capsules should not be broken, crushed, chewed, or dissolved, as this would affect the integrity of the formulation.[15] The medication is generally recommended to be taken with meals to enhance absorption and improve gastrointestinal tolerability.[4]
• Ancillary Measures: Pharmacotherapy with omega-3-acid ethyl esters is an adjunct to, not a replacement for, lifestyle modification. Patients must be placed on an appropriate lipid-lowering diet before therapy is initiated and should continue this diet throughout the course of treatment.[12]

Distinction from Dietary Supplements

It is of paramount clinical importance to distinguish the prescription pharmaceutical product from over-the-counter (OTC) fish oil supplements.

• Regulation and Purity: Prescription Lovaza and its generics are FDA-approved drugs manufactured under strict Good Manufacturing Practices. Their composition is highly purified and standardized, with a verified concentration of at least 900 mg of specific omega-3-acid ethyl esters per 1-gram capsule, and a precisely defined API containing at least seven components.[18] In contrast, OTC fish oil supplements are regulated as dietary supplements, a less stringent category. Their content can be highly variable, purity is not always independently verified, and they may contain lower concentrations of EPA and DHA and higher levels of other fats or potential contaminants.[33]
• Clinical Evidence: All the clinical trial data, efficacy claims, and safety warnings (such as the risk of atrial fibrillation and increased LDL-C) discussed in this report apply specifically to the prescription-strength, standardized pharmaceutical product. This evidence cannot and should not be extrapolated to the vast and heterogeneous market of OTC supplements.[13]
• Strength and Dose: Achieving the therapeutic dose of 4 grams of omega-3-acid ethyl esters per day is feasible with four capsules of the prescription product. Achieving a similar dose of EPA and DHA from typical OTC supplements would often require ingesting a much larger number of capsules, which may be impractical and would also introduce a higher load of other, non-therapeutic fatty acids.

Synthesis and Concluding Remarks

Omega-3-acid ethyl esters occupy a well-defined but increasingly narrow niche in modern pharmacotherapy. The agent is unequivocally an effective and well-established treatment for the specific metabolic disorder of severe hypertriglyceridemia (sHTG). Its triglyceride-lowering mechanism, centered on modulating hepatic lipid synthesis and metabolism, is well-understood, and its ability to reduce triglyceride levels by 20-45% in patients with sHTG is supported by a robust and consistent body of clinical evidence. In this context, its primary clinical utility is the management of markedly elevated triglyceride levels to mitigate the associated metabolic consequences, including the theoretical reduction of pancreatitis risk.

However, the journey of omega-3-acid ethyl esters beyond this indication has been marked by controversy and disappointment. The initial promise for its use in broader cardiovascular risk reduction, fueled by early and less rigorous trials, has not been substantiated by the weight of modern, high-quality evidence from large-scale cardiovascular outcome trials. The consistent failure to demonstrate a significant benefit in major cardiovascular endpoints stands in stark contrast to the success of the EPA-only formulation, icosapent ethyl, in the REDUCE-IT trial. This disparity has led to a major regulatory divergence, with European authorities formally revoking the post-myocardial infarction indication, cementing the conclusion that this specific EPA/DHA combination is not an effective therapy for general cardiovascular protection.

The therapeutic landscape for this drug has been further reshaped by the emergence of a new safety paradigm. The identification of a dose-dependent increased risk of atrial fibrillation has fundamentally altered the drug's risk-benefit calculation. Omega-3-acid ethyl esters can no longer be viewed as a benign, "natural" agent. It is a potent drug with a significant, quantifiable risk that requires careful patient selection, informed consent regarding the potential for arrhythmia, and diligent monitoring. The clinical mandate to permanently discontinue therapy should atrial fibrillation develop underscores the seriousness of this adverse effect.

In its current place in therapy, omega-3-acid ethyl esters should be considered a second-line or adjunctive agent, reserved for patients with severe hypertriglyceridemia where the primary therapeutic goal is triglyceride reduction itself. The decision to initiate treatment must now involve a comprehensive discussion with the patient, weighing the established benefit of triglyceride lowering against the potential risks of an increase in LDL-cholesterol and the newly quantified risk of developing atrial fibrillation.

Future research should focus on clarifying the remaining uncertainties. Head-to-head trials directly comparing the cardiovascular and arrhythmogenic effects of high-dose EPA/DHA formulations versus EPA-only formulations are needed to resolve the debate over the role of DHA. Furthermore, prospective validation of the "responder" hypothesis, using the red blood cell omega-3 index as a biomarker to guide therapy, could potentially identify a subpopulation of patients in whom the drug might still offer a net benefit, paving the way for a more personalized approach to its use. Until such data are available, the clinical application of omega-3-acid ethyl esters should remain focused on its single, proven indication, with heightened vigilance for its associated risks.

Works cited

1. Fatty Liver, Nonalcoholic Completed Phase 4 Trials for Omega-3-acid ethyl esters (DB09539) - DrugBank, accessed August 8, 2025, https://go.drugbank.com/indications/DBCOND0070024/clinical_trials/DB09539?phase=4&status=completed
2. MI Completed Phase 3 Trials for Omega-3-acid ethyl esters (DB09539) | DrugBank Online, accessed August 8, 2025, https://go.drugbank.com/indications/DBCOND0021996/clinical_trials/DB09539?phase=3&status=completed
3. Omega-3-Acid Ethyl Esters: Package Insert / Prescribing Info - Drugs.com, accessed August 8, 2025, https://www.drugs.com/pro/omega-3-acid-ethyl-esters.html
4. Omega-3-acid ethyl esters: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 8, 2025, https://go.drugbank.com/drugs/DB09539
5. Omega-3 Acid Ethyl Esters, accessed August 8, 2025, https://www.drugfuture.com/chemdata/omega-3-acid-ethyl-esters.html
6. CAS 308081-97-2 Omega-3-Acid Ethyl Esters - Alfa Chemistry, accessed August 8, 2025, https://www.alfa-chemistry.com/cas_308081-97-2.htm
7. Pharm-Rx Omega-3-Acid-Ethyl Esters - 308081-97-2, accessed August 8, 2025, https://www.pharm-rx.store/products/pharm-rx-omega-3-acid-ethyl-esters
8. Pharm-Rx Omega-3-Acid-Ethyl Esters - 308081-97-2 - Knowde, accessed August 8, 2025, https://www.knowde.com/stores/pharm-rx/products/pharm-rx-omega-3-acid-ethyl-esters
9. Polyunsaturated ω-3 fatty acids, Et esters - CAS Common Chemistry, accessed August 8, 2025, https://commonchemistry.cas.org/detail?cas_rn=308081-97-2
10. Omega-3-Acid Ethyl Esters (Lovaza, Omacor, Triklo) - WebMD, accessed August 8, 2025, https://www.webmd.com/drugs/2/drug-92326/omega-3-acid-ethyl-esters-oral/details
11. Lovaza (omega 3 fatty acids) dosing, indications, interactions, adverse effects, and more, accessed August 8, 2025, https://reference.medscape.com/drug/lovaza-omega-3-fatty-acids-342455
12. Lovaza (Omega-3-Acid Ethyl Esters): Side Effects, Uses, Dosage ..., accessed August 8, 2025, https://www.rxlist.com/lovaza-drug.htm
13. Omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000mg capsules): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors - GOV.UK, accessed August 8, 2025, https://www.gov.uk/drug-safety-update/omega-3-acid-ethyl-ester-medicines-omacor-slash-teromeg-1000mg-capsules-dose-dependent-increased-risk-of-atrial-fibrillation-in-patients-with-established-cardiovascular-diseases-or-cardiovascular-risk-factors
14. www.cancer.gov, accessed August 8, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/omega-3-acid-ethyl-esters#:~:text=An%20ethyl%20ester%20form%20of,fats%20made%20in%20the%20liver.
15. Omega-3-acid Ethyl Esters Monograph for Professionals - Drugs.com, accessed August 8, 2025, https://www.drugs.com/monograph/omega-3-acid-ethyl-esters.html
16. (PDF) Omacor (omega-3-acid ethyl esters) - ResearchGate, accessed August 8, 2025, https://www.researchgate.net/publication/238632162_Omacor_omega-3-acid_ethyl_esters
17. 2 LOVAZA® - accessdata.fda.gov, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021654s023lbl.pdf
18. Omega-3-acid ethyl esters Oral Capsule - accessdata.fda.gov, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021654.pdf
19. Lovaza | C46H70O4 | CID 9831414 - PubChem, accessed August 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Lovaza
20. Icosapent Ethyl | C22H34O2 | CID 9831415 - PubChem, accessed August 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Icosapent-Ethyl
21. Eicosapentaenoic Acid Ethyl Ester (500 mg) - USP Store, accessed August 8, 2025, https://store.usp.org/product/1234307
22. Docosahexaenoic acid ethyl ester | C24H36O2 | CID 121839 ..., accessed August 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Docosahexaenoic-acid-ethyl-ester
23. Docosahexaenoic Acid ethyl ester | CAS 81926-94-5 | SCBT, accessed August 8, 2025, https://www.scbt.com/p/docosahexaenoic-acid-ethyl-ester-1020718-25-5
24. Compound: OMEGA-3-ACID ETHYL ESTERS (CHEMBL1200711) - ChEMBL - EMBL-EBI, accessed August 8, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1200711
25. Docosahexaenoic acid ethyl ester (Synonyms - MedchemExpress.com, accessed August 8, 2025, https://www.medchemexpress.com/docosahexaenoic-acid-ethyl-ester.html
26. Docosahexaenoic Acid Ethyl Ester, 81926-94-5 - BroadPharm, accessed August 8, 2025, https://broadpharm.com/product/BP-29834
27. Definition of omega-3-acid ethyl esters - NCI Drug Dictionary, accessed August 8, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/omega-3-acid-ethyl-esters
28. Omega-3-acid ethyl esters - Wikipedia, accessed August 8, 2025, https://en.wikipedia.org/wiki/Omega-3-acid_ethyl_esters
29. Omega 3-acid-ethyl esters 1000mg soft capsules - Summary of Product Characteristics (SmPC) - (emc) | 14387, accessed August 8, 2025, https://www.medicines.org.uk/emc/product/14387/smpc
30. Omega-3 EMEA/H/A-31/1464 - European Union, accessed August 8, 2025, https://ec.europa.eu/health/documents/community-register/2019/20190606143568/anx_143568_en.pdf
31. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5383544/
32. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients - J-Stage, accessed August 8, 2025, https://www.jstage.jst.go.jp/article/jat/24/3/24_34231/_article
33. Lovaza vs. Vascepa: Which Fish Oil Should You Take? - GoodRx, accessed August 8, 2025, https://www.goodrx.com/conditions/high-triglycerides/lovaza-vascepa-lowering-triglycerides
34. About LOVAZA® - LOVAZA®, accessed August 8, 2025, https://lovaza.com/about/
35. Safety - LOVAZA®, accessed August 8, 2025, https://lovaza.com/safety/
36. Omega-3-Acid Ethyl Esters: Triglyceride Uses & Side Effects - MedicineNet, accessed August 8, 2025, https://www.medicinenet.com/omega-3-acid_ethyl_esters_lovaza/article.htm
37. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid | Arteriosclerosis, Thrombosis, and Vascular Biology - American Heart Association Journals, accessed August 8, 2025, https://www.ahajournals.org/doi/10.1161/ATVBAHA.119.313286
38. Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8035073/
39. Omega-3 Fatty Acids | C60H92O6 | CID 56842239 - PubChem, accessed August 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/56842239
40. Approval Package for: ANDA 91028 - accessdata.fda.gov, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/091028Orig1s000-part1.pdf
41. Clinical Policy: Omega-3-Aacid eEthyl eEsters (Lovaza) Reference Number - NH Healthy Families, accessed August 8, 2025, https://www.nhhealthyfamilies.com/content/dam/centene/NH%20Healthy%20Families/Medicaid/pdfs/CP.PMN.52%20Omega-3-acid%20ethyl%20esters%20(Lovaza)%20Q3%202017.pdf
42. Efficacy and safety of omega-3-acid ethyl acetate 90 capsules in severe hypertriglyceridemia: A randomized, controlled, multicenter study - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/38830807
43. Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides (OMEELVHT) - ClinicalTrials.gov, accessed August 8, 2025, https://www.clinicaltrials.gov/study/NCT02625870
44. EMA concludes omega-3 fatty acids medicines no longer considered effective in preventing heart disease, accessed August 8, 2025, https://medicinesauthority.gov.mt/file.aspx?f=4149
45. Effect of six month's treatment with omega-3 acid ethyl esters on long-term outcomes after acute myocardial infarction: The OMEGA-REMODEL randomized clinical trial - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/38184150/
46. Recent Clinical Trials Shed New Light on the Cardiovascular ..., accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6822654/
47. Omega-3-acid ethyl esters Completed Phase Trials for Cardiovascular Diseases Basic Science | DrugBank Online, accessed August 8, 2025, https://go.drugbank.com/drugs/DB09539/clinical_trials?conditions=DBCOND0027859&phase=&purpose=basic_science&status=completed
48. Biliary Cancers Unknown Status Phase 2 Trials for Omega-3-acid ethyl esters (DB09539), accessed August 8, 2025, https://go.drugbank.com/indications/DBCOND0105412/clinical_trials/DB09539?phase=2&status=unknown_status
49. Clinical Trials Using Omega-3-Acid Ethyl Esters - NCI, accessed August 8, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/omega-3-acid-ethyl-esters?pn=1
50. Study Details | Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation | ClinicalTrials.gov, accessed August 8, 2025, https://www.clinicaltrials.gov/study/NCT00402363
51. Omega-3-acid ethyl esters Advanced Patient Information - Drugs.com, accessed August 8, 2025, https://www.drugs.com/cons/omega-3-acid-ethyl-esters.html
52. Lovaza Uses, Side Effects & Warnings - Drugs.com, accessed August 8, 2025, https://www.drugs.com/mtm/lovaza.html
53. EMA warns that omega-3-acid ethyl esters may cause AFib | MDedge, accessed August 8, 2025, https://www.mdedge.com/clinicalendocrinologynews/article/265910/arrhythmias-ep/ema-warns-omega-3-acid-ethyl-esters-may
54. EMA warns that omega-3-acid ethyl esters may cause AFib | MDedge - The Hospitalist, accessed August 8, 2025, https://blogs.the-hospitalist.org/content/ema-warns-omega-3-acid-ethyl-esters-may-cause-afib
55. Safety update: omega-3-acid ethyl esters and atrial fibrillation - Drug and Therapeutics Bulletin, accessed August 8, 2025, https://dtb.bmj.com/content/dtb/early/2024/02/07/dtb.2024.000010.full.pdf
56. Omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000 mg capsules): dose-dependent increased risk of at - GOV.UK, accessed August 8, 2025, https://assets.publishing.service.gov.uk/media/65ce2350c96cf300126a3820/Omacor_-_TO_PUBLISH.pdf
57. New safety information for omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000 mg capsules) - GOV.UK, accessed August 8, 2025, https://www.gov.uk/government/news/new-safety-information-for-omega-3-acid-ethyl-ester-medicines-omacorteromeg-1000-mg-capsules
58. Medicines containing omega-3 fatty acids: dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular, accessed August 8, 2025, https://www.edaegypt.gov.eg/media/faphu1bx/dhpc-omega-3-fatty-acids.pdf
59. Omega-3-acid ethyl esters (oral route) - Side effects & dosage - Mayo Clinic, accessed August 8, 2025, https://www.mayoclinic.org/drugs-supplements/omega-3-acid-ethyl-esters-oral-route/description/drg-20066973
60. Omacor (omega-3-acid ethyl esters) FDA Approval History - Drugs ..., accessed August 8, 2025, https://www.drugs.com/history/omacor.html
61. Drug Approval Package: Omacor (Omega-3-Acid Ethyl Esters) NDA #021654, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-654_Omacor.cfm
62. Omega-3-acid Ethyl Esters (Lovaza) For Severe Hypertriglyceridemia - PMC, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2683599/
63. Generic Lovaza Availability - Drugs.com, accessed August 8, 2025, https://www.drugs.com/availability/generic-lovaza.html
64. Omega-3 fatty acid ethyl esters - direct healthcare professional communication (DHPC), accessed August 8, 2025, https://www.ema.europa.eu/en/medicines/dhpc/omega-3-fatty-acid-ethyl-esters